Ixazomib

INSIGHT-MM: real-world analysis of DOT with Rd-based regimens in R/R myeloma 4:12
INSIGHT-MM: real-world analysis of DOT with Rd-based regimens in R/R myeloma
Noemí Puig • 8 Jun 2021
Final analysis of UVEA-IXA study of ixazomib in R/R myeloma 4:19
Final analysis of UVEA-IXA study of ixazomib in R/R myeloma
Heinz Ludwig • 1 Jun 2021
MRD evaluation during ixazomib maintenance in myeloma 2:53
MRD evaluation during ixazomib maintenance in myeloma
Bruno Paiva • 28 May 2021
DARIA: second-line dara plus ixazomib and dex in len-refractory myeloma patients 2:17
DARIA: second-line dara plus ixazomib and dex in len-refractory myeloma patients
Evangelos Terpos • 7 Jun 2021
BMT CTN 1302: maintenance ixazomib following alloHCT in patients with high-risk myeloma 3:50
BMT CTN 1302: maintenance ixazomib following alloHCT in patients with high-risk myeloma
Taiga Nishihori • 20 May 2021
The management of multiple myeloma in 2021 2:15
The management of multiple myeloma in 2021
Claudio Cerchione • 25 May 2021
Treatment options for relapsed young myeloma 3:39
Treatment options for relapsed young myeloma
Muzaffar Qazilbash • 12 May 2021
Treating elderly myeloma: frailty scoring and latest trial data 6:11
Treating elderly myeloma: frailty scoring and latest trial data
Meral Beksac • 10 May 2021
New approaches to the treatment of elderly myeloma 5:07
New approaches to the treatment of elderly myeloma
Meral Beksac • 10 May 2021
Do HDAC inhibitors still have a place in the treatment of myeloma? 4:30
Do HDAC inhibitors still have a place in the treatment of myeloma?
Enrique Ocio • 16 Apr 2021
Proteasome inhibitors in elderly patients with multiple myeloma 1:50
Proteasome inhibitors in elderly patients with multiple myeloma
Maria-Victoria Mateos • 30 Apr 2021
Challenges associated with Waldenström’s 4:07
Challenges associated with Waldenström’s
Jorge Castillo • 16 Apr 2021
Current state of the art for WM 3:46
Current state of the art for WM
Jorge Castillo • 16 Apr 2021
Unravelling drug resistance and sensitization 2:15
Unravelling drug resistance and sensitization
Michel Delforge • 10 Mar 2021
Horizon scan: multiple myeloma treatment landscape 3:20
Horizon scan: multiple myeloma treatment landscape
Claudio Cerchione • 3 Mar 2021
Maintenance therapy in young patients with myeloma 4:55
Maintenance therapy in young patients with myeloma
Graham Jackson • 5 Mar 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals